Related Experiment Videos

Tiamulin inhibits human CYP3A4 activity in an NIH/3T3 cell line stably expressing CYP3A4 cDNA

E M De Groene1, S M Nijmeijer, G J Horbach

  • 1Research Institute of Toxicology, Utrecht University, The Netherlands.

Biochemical Pharmacology
|September 7, 1995
PubMed

Insights

Tiamulin, a veterinary antibiotic, inhibits human cytochrome P450 (CYP3A4) activity and blocks CYP3A4-mediated aflatoxin B1 mutagenicity. This suggests tiamulin binds to the cytochrome, impacting drug metabolism and safety.

Area of Science:

  • Pharmacology
  • Biochemistry
  • Drug Metabolism

Background:

  • Tiamulin is a veterinary antibiotic with known drug interaction potential.
  • Cytochrome P450 enzymes, particularly CYP3A4, are crucial for drug metabolism.
  • Understanding tiamulin's impact on CYP3A4 is vital for veterinary drug safety.

Purpose of the Study:

  • To investigate the effect of tiamulin on human CYP3A4 activity.
  • To determine if tiamulin affects CYP3A4-mediated mutagenicity.
  • To elucidate the mechanism of tiamulin's interaction with CYP3A4.

Main Methods:

  • Utilized an NIH/3T3 cell line stably expressing human CYP3A4.
  • Assessed testosterone 6 beta-hydroxylation activity in the presence of varying tiamulin concentrations.
  • Evaluated tiamulin's effect on aflatoxin B1 mutagenicity using a bacterial lacZ' gene assay.
  • Performed Western blotting to analyze CYP3A4 protein levels.

Main Results:

  • Tiamulin significantly reduced CYP3A4-mediated testosterone 6 beta-hydroxylation in a dose-dependent manner.
  • Tiamulin completely inhibited CYP3A4-mediated aflatoxin B1 mutagenicity.
  • No effect of tiamulin was observed on the mutagenicity of ethylmethanesulphonate.
  • Western blot analysis indicated tiamulin stabilizes CYP3A4 protein.

Conclusions:

  • Tiamulin inhibits human CYP3A4 activity and its metabolic activation of aflatoxin B1.
  • The mechanism of inhibition appears to involve tiamulin binding to the cytochrome.
  • These findings highlight potential drug interactions and safety concerns for tiamulin in co-administered therapies.

Related Concept Videos